Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Immunogen affinity purified
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for DR6/TNFRSF21 Antibody
Death receptor 6
DR6TNFR-related death receptor 6
tumor necrosis factor receptor superfamily member 21
tumor necrosis factor receptor superfamily, member 21
Death Receptor 6 (DR6), also known as TNFRSF21 and CD358, is a type I transmembrane protein in the TNF receptor superfamily (1). Human DR6 consists of a 308 amino acid (aa) extracellular domain (ECD) with four cysteine‑rich motifs, a 21 aa transmembrane segment, and a 285 aa palmitylated cytoplasmic region that contains one death domain (2, 3). Within the ECD, human and mouse DR6 share 82% aa sequence identity. DR6 is expressed as an approximately 110 kDa molecule that carries extensive N‑linked and O‑linked glycosylation in its extracellular region (3, 4). Among hematopoietic cells, DR6 is expressed on monocytes, resting CD4+ T cells, and pro‑, pre‑, and naïve B cells (5 ‑ 7). DR6 knockout mice exhibit a Th2‑biased immune response characterized by exaggerated Th2 and B cell responsiveness in combination with reduced Th1 cell responsiveness and inflammatory leukocyte infiltration (6 ‑ 9). DR6 knockout mice are resistant to induced airway inflammation and experimental autoimmune encephalitis but more susceptible to severe graft versus host disease (9 ‑ 11). DR6 is also expressed on developing neurons where it can bind a shed 35 kDa N‑terminal fragment of APP or a fragment of APLP2 (12, 13). This APP fragment is generated following deprivation of neurotrophic factors, and its binding to DR6 triggers DR6‑mediated axonal pruning (12). DR6 is constitutively expressed on some prostate cancer cells and can be induced by TNF‑ alpha on others (3, 4).
Benschop, R. et al. (2009) Adv. Exp. Med. Biol. 647:186.
Pan, G. et al. (1998) FEBS Lett. 431:351.
Klima, M. et al. (2009) Biochim. Biophys. Acta 1793:1579.
Kasof, G.M. et al. (2001) Oncogene 20:7965.
Matesanz-Isabel, J. et al. (2011) Immunol. Lett. 134:104.
Schmidt, C.S. et al. (2003) J. Exp. Med. 197:51.
Liu, J. et al. (2001) Immunity 15:23.
Zhao, H. et al. (2001) J. Exp. Med. 194:1441.
Venkataraman, C. et al. (2006) Immunol. Lett. 106:42.
Schmidt, C.S. et al. (2005) J. Immunol. 175:2286.
Liu, J. et al. (2002) J. Immunol. 169:3993.
Nikolaev, A. et al. (2009) Nature 457:981.
Kuester, M. et al. (2011) J. Mol. Biol. 409:189.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our DR6/TNFRSF21 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.